English
简体中文
Total: £ 56.28
Published Date: 2025-11-07 | Pages: 157 | Tables: 156 | Medical Care
The global Small Molecule Drug CDMO Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Small molecule drug CDMO services refer to outsourcing services for the development and production of small molecule drugs. CDMO (Contract Development and Manufacturing Organization) is a third-party organization that specializes in drug development and production. It provides customized services to pharmaceutical companies, covering the entire process from the drug development stage to the commercial production stage. CDMO services for small molecule drugs usually include drug development support, clinical trial support, production process optimization, commercial production, quality control and compliance support. By choosing CDMO services, pharmaceutical companies can focus on their core business and outsource drug R&D and production to professional organizations, thereby improving efficiency, reducing risks, and accelerating the launch of new drugs.
From a downstream perspective, Clinical Treatment accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Small Molecule Drug CDMO Services leading manufacturers including Gliead, Boehringer Ingelheim, Vertex, Mirati Therapeutics, AMPAC, Pfizer, Polypeptide, Bachem, Merck, Asymchem, etc., dominate supply; the top five capture approximately % of global revenue, with Gliead leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Small Molecule Drug CDMO Services market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Thermo Fisher Scientific
Zhejiang Jiuzhou Pharmaceutical
Porton Fine Chemicals
Lonza Group
JOINN Biologics
Zhejiang Langhua Pharmaceutical
Kingchem (Liaoning) Life Science
Segment by Type
Preparation
Chemical API
Segment by Application
Clinical Treatment
Medical Research
Commercial Production
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Small Molecule Drug CDMO Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Small Molecule Drug CDMO Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Small Molecule Drug CDMO Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Preparation
1.2.3 Chemical API
1.3 Market Segmentation by Application
1.3.1 Global Small Molecule Drug CDMO Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinical Treatment
1.3.3 Medical Research
1.3.4 Commercial Production
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Small Molecule Drug CDMO Services Revenue Estimates and Forecasts 2020-2031
2.2 Global Small Molecule Drug CDMO Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Small Molecule Drug CDMO Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Small Molecule Drug CDMO Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Preparation Market Size by Players
3.3.2 Chemical API Market Size by Players
3.4 Global Small Molecule Drug CDMO Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Small Molecule Drug CDMO Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Small Molecule Drug CDMO Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Small Molecule Drug CDMO Services Market Size by Type (2020-2031)
6.4 North America Small Molecule Drug CDMO Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Small Molecule Drug CDMO Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Small Molecule Drug CDMO Services Market Size by Type (2020-2031)
7.4 Europe Small Molecule Drug CDMO Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Small Molecule Drug CDMO Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Small Molecule Drug CDMO Services Market Size by Type (2020-2031)
8.4 Asia-Pacific Small Molecule Drug CDMO Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Small Molecule Drug CDMO Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Small Molecule Drug CDMO Services Market Size by Type (2020-2031)
9.4 Central and South America Small Molecule Drug CDMO Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Small Molecule Drug CDMO Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Small Molecule Drug CDMO Services Market Size by Type (2020-2031)
10.4 Middle East and Africa Small Molecule Drug CDMO Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Small Molecule Drug CDMO Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Gliead
11.1.1 Gliead Corporation Information
11.1.2 Gliead Business Overview
11.1.3 Gliead Small Molecule Drug CDMO Services Product Features and Attributes
11.1.4 Gliead Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.1.5 Gliead Small Molecule Drug CDMO Services Revenue by Product in 2024
11.1.6 Gliead Small Molecule Drug CDMO Services Revenue by Application in 2024
11.1.7 Gliead Small Molecule Drug CDMO Services Revenue by Geographic Area in 2024
11.1.8 Gliead Small Molecule Drug CDMO Services SWOT Analysis
11.1.9 Gliead Recent Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Corporation Information
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Small Molecule Drug CDMO Services Product Features and Attributes
11.2.4 Boehringer Ingelheim Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.2.5 Boehringer Ingelheim Small Molecule Drug CDMO Services Revenue by Product in 2024
11.2.6 Boehringer Ingelheim Small Molecule Drug CDMO Services Revenue by Application in 2024
11.2.7 Boehringer Ingelheim Small Molecule Drug CDMO Services Revenue by Geographic Area in 2024
11.2.8 Boehringer Ingelheim Small Molecule Drug CDMO Services SWOT Analysis
11.2.9 Boehringer Ingelheim Recent Developments
11.3 Vertex
11.3.1 Vertex Corporation Information
11.3.2 Vertex Business Overview
11.3.3 Vertex Small Molecule Drug CDMO Services Product Features and Attributes
11.3.4 Vertex Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.3.5 Vertex Small Molecule Drug CDMO Services Revenue by Product in 2024
11.3.6 Vertex Small Molecule Drug CDMO Services Revenue by Application in 2024
11.3.7 Vertex Small Molecule Drug CDMO Services Revenue by Geographic Area in 2024
11.3.8 Vertex Small Molecule Drug CDMO Services SWOT Analysis
11.3.9 Vertex Recent Developments
11.4 Mirati Therapeutics
11.4.1 Mirati Therapeutics Corporation Information
11.4.2 Mirati Therapeutics Business Overview
11.4.3 Mirati Therapeutics Small Molecule Drug CDMO Services Product Features and Attributes
11.4.4 Mirati Therapeutics Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.4.5 Mirati Therapeutics Small Molecule Drug CDMO Services Revenue by Product in 2024
11.4.6 Mirati Therapeutics Small Molecule Drug CDMO Services Revenue by Application in 2024
11.4.7 Mirati Therapeutics Small Molecule Drug CDMO Services Revenue by Geographic Area in 2024
11.4.8 Mirati Therapeutics Small Molecule Drug CDMO Services SWOT Analysis
11.4.9 Mirati Therapeutics Recent Developments
11.5 AMPAC
11.5.1 AMPAC Corporation Information
11.5.2 AMPAC Business Overview
11.5.3 AMPAC Small Molecule Drug CDMO Services Product Features and Attributes
11.5.4 AMPAC Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.5.5 AMPAC Small Molecule Drug CDMO Services Revenue by Product in 2024
11.5.6 AMPAC Small Molecule Drug CDMO Services Revenue by Application in 2024
11.5.7 AMPAC Small Molecule Drug CDMO Services Revenue by Geographic Area in 2024
11.5.8 AMPAC Small Molecule Drug CDMO Services SWOT Analysis
11.5.9 AMPAC Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Small Molecule Drug CDMO Services Product Features and Attributes
11.6.4 Pfizer Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.6.5 Pfizer Recent Developments
11.7 Polypeptide
11.7.1 Polypeptide Corporation Information
11.7.2 Polypeptide Business Overview
11.7.3 Polypeptide Small Molecule Drug CDMO Services Product Features and Attributes
11.7.4 Polypeptide Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.7.5 Polypeptide Recent Developments
11.8 Bachem
11.8.1 Bachem Corporation Information
11.8.2 Bachem Business Overview
11.8.3 Bachem Small Molecule Drug CDMO Services Product Features and Attributes
11.8.4 Bachem Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.8.5 Bachem Recent Developments
11.9 Merck
11.9.1 Merck Corporation Information
11.9.2 Merck Business Overview
11.9.3 Merck Small Molecule Drug CDMO Services Product Features and Attributes
11.9.4 Merck Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.9.5 Merck Recent Developments
11.10 Asymchem
11.10.1 Asymchem Corporation Information
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Small Molecule Drug CDMO Services Product Features and Attributes
11.10.4 Asymchem Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Thermo Fisher Scientific
11.11.1 Thermo Fisher Scientific Corporation Information
11.11.2 Thermo Fisher Scientific Business Overview
11.11.3 Thermo Fisher Scientific Small Molecule Drug CDMO Services Product Features and Attributes
11.11.4 Thermo Fisher Scientific Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.11.5 Thermo Fisher Scientific Recent Developments
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Corporation Information
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Small Molecule Drug CDMO Services Product Features and Attributes
11.12.4 Zhejiang Jiuzhou Pharmaceutical Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Developments
11.13 Porton Fine Chemicals
11.13.1 Porton Fine Chemicals Corporation Information
11.13.2 Porton Fine Chemicals Business Overview
11.13.3 Porton Fine Chemicals Small Molecule Drug CDMO Services Product Features and Attributes
11.13.4 Porton Fine Chemicals Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.13.5 Porton Fine Chemicals Recent Developments
11.14 Lonza Group
11.14.1 Lonza Group Corporation Information
11.14.2 Lonza Group Business Overview
11.14.3 Lonza Group Small Molecule Drug CDMO Services Product Features and Attributes
11.14.4 Lonza Group Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.14.5 Lonza Group Recent Developments
11.15 JOINN Biologics
11.15.1 JOINN Biologics Corporation Information
11.15.2 JOINN Biologics Business Overview
11.15.3 JOINN Biologics Small Molecule Drug CDMO Services Product Features and Attributes
11.15.4 JOINN Biologics Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.15.5 JOINN Biologics Recent Developments
11.16 Zhejiang Langhua Pharmaceutical
11.16.1 Zhejiang Langhua Pharmaceutical Corporation Information
11.16.2 Zhejiang Langhua Pharmaceutical Business Overview
11.16.3 Zhejiang Langhua Pharmaceutical Small Molecule Drug CDMO Services Product Features and Attributes
11.16.4 Zhejiang Langhua Pharmaceutical Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.16.5 Zhejiang Langhua Pharmaceutical Recent Developments
11.17 Kingchem (Liaoning) Life Science
11.17.1 Kingchem (Liaoning) Life Science Corporation Information
11.17.2 Kingchem (Liaoning) Life Science Business Overview
11.17.3 Kingchem (Liaoning) Life Science Small Molecule Drug CDMO Services Product Features and Attributes
11.17.4 Kingchem (Liaoning) Life Science Small Molecule Drug CDMO Services Revenue and Gross Margin (2020-2025)
11.17.5 Kingchem (Liaoning) Life Science Recent Developments
12 Small Molecule Drug CDMO ServicesIndustry Chain Analysis
12.1 Small Molecule Drug CDMO Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Small Molecule Drug CDMO Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Small Molecule Drug CDMO Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Small Molecule Drug CDMO Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Small Molecule Drug CDMO Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Small Molecule Drug CDMO Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Small Molecule Drug CDMO Services Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Small Molecule Drug CDMO Services Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Small Molecule Drug CDMO Services Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Small Molecule Drug CDMO Services Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Small Molecule Drug CDMO Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Small Molecule Drug CDMO Services as of 2024)
Table 11. Global Small Molecule Drug CDMO Services Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Small Molecule Drug CDMO Services Companies Headquarters
Table 13. Global Small Molecule Drug CDMO Services Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Small Molecule Drug CDMO Services Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Small Molecule Drug CDMO Services Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Small Molecule Drug CDMO Services Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Small Molecule Drug CDMO Services Revenue by Application (2026-2031) & (US$ Million)
Table 21. Small Molecule Drug CDMO Services High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Small Molecule Drug CDMO Services Growth Accelerators and Market Barriers
Table 25. North America Small Molecule Drug CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Small Molecule Drug CDMO Services Growth Accelerators and Market Barriers
Table 27. Europe Small Molecule Drug CDMO Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Small Molecule Drug CDMO Services Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Small Molecule Drug CDMO Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Small Molecule Drug CDMO Services Investment Opportunities and Key Challenges
Table 31. Central and South America Small Molecule Drug CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Small Molecule Drug CDMO Services Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Small Molecule Drug CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Gliead Corporation Information
Table 35. Gliead Description and Major Businesses
Table 36. Gliead Product Features and Attributes
Table 37. Gliead Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Gliead Revenue Proportion by Product in 2024
Table 39. Gliead Revenue Proportion by Application in 2024
Table 40. Gliead Revenue Proportion by Geographic Area in 2024
Table 41. Gliead Small Molecule Drug CDMO Services SWOT Analysis
Table 42. Gliead Recent Developments
Table 43. Boehringer Ingelheim Corporation Information
Table 44. Boehringer Ingelheim Description and Major Businesses
Table 45. Boehringer Ingelheim Product Features and Attributes
Table 46. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Boehringer Ingelheim Revenue Proportion by Product in 2024
Table 48. Boehringer Ingelheim Revenue Proportion by Application in 2024
Table 49. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2024
Table 50. Boehringer Ingelheim Small Molecule Drug CDMO Services SWOT Analysis
Table 51. Boehringer Ingelheim Recent Developments
Table 52. Vertex Corporation Information
Table 53. Vertex Description and Major Businesses
Table 54. Vertex Product Features and Attributes
Table 55. Vertex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Vertex Revenue Proportion by Product in 2024
Table 57. Vertex Revenue Proportion by Application in 2024
Table 58. Vertex Revenue Proportion by Geographic Area in 2024
Table 59. Vertex Small Molecule Drug CDMO Services SWOT Analysis
Table 60. Vertex Recent Developments
Table 61. Mirati Therapeutics Corporation Information
Table 62. Mirati Therapeutics Description and Major Businesses
Table 63. Mirati Therapeutics Product Features and Attributes
Table 64. Mirati Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Mirati Therapeutics Revenue Proportion by Product in 2024
Table 66. Mirati Therapeutics Revenue Proportion by Application in 2024
Table 67. Mirati Therapeutics Revenue Proportion by Geographic Area in 2024
Table 68. Mirati Therapeutics Small Molecule Drug CDMO Services SWOT Analysis
Table 69. Mirati Therapeutics Recent Developments
Table 70. AMPAC Corporation Information
Table 71. AMPAC Description and Major Businesses
Table 72. AMPAC Product Features and Attributes
Table 73. AMPAC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. AMPAC Revenue Proportion by Product in 2024
Table 75. AMPAC Revenue Proportion by Application in 2024
Table 76. AMPAC Revenue Proportion by Geographic Area in 2024
Table 77. AMPAC Small Molecule Drug CDMO Services SWOT Analysis
Table 78. AMPAC Recent Developments
Table 79. Pfizer Corporation Information
Table 80. Pfizer Description and Major Businesses
Table 81. Pfizer Product Features and Attributes
Table 82. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Pfizer Recent Developments
Table 84. Polypeptide Corporation Information
Table 85. Polypeptide Description and Major Businesses
Table 86. Polypeptide Product Features and Attributes
Table 87. Polypeptide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Polypeptide Recent Developments
Table 89. Bachem Corporation Information
Table 90. Bachem Description and Major Businesses
Table 91. Bachem Product Features and Attributes
Table 92. Bachem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Bachem Recent Developments
Table 94. Merck Corporation Information
Table 95. Merck Description and Major Businesses
Table 96. Merck Product Features and Attributes
Table 97. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Merck Recent Developments
Table 99. Asymchem Corporation Information
Table 100. Asymchem Description and Major Businesses
Table 101. Asymchem Product Features and Attributes
Table 102. Asymchem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Asymchem Recent Developments
Table 104. Thermo Fisher Scientific Corporation Information
Table 105. Thermo Fisher Scientific Description and Major Businesses
Table 106. Thermo Fisher Scientific Product Features and Attributes
Table 107. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Thermo Fisher Scientific Recent Developments
Table 109. Zhejiang Jiuzhou Pharmaceutical Corporation Information
Table 110. Zhejiang Jiuzhou Pharmaceutical Description and Major Businesses
Table 111. Zhejiang Jiuzhou Pharmaceutical Product Features and Attributes
Table 112. Zhejiang Jiuzhou Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Zhejiang Jiuzhou Pharmaceutical Recent Developments
Table 114. Porton Fine Chemicals Corporation Information
Table 115. Porton Fine Chemicals Description and Major Businesses
Table 116. Porton Fine Chemicals Product Features and Attributes
Table 117. Porton Fine Chemicals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Porton Fine Chemicals Recent Developments
Table 119. Lonza Group Corporation Information
Table 120. Lonza Group Description and Major Businesses
Table 121. Lonza Group Product Features and Attributes
Table 122. Lonza Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Lonza Group Recent Developments
Table 124. JOINN Biologics Corporation Information
Table 125. JOINN Biologics Description and Major Businesses
Table 126. JOINN Biologics Product Features and Attributes
Table 127. JOINN Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. JOINN Biologics Recent Developments
Table 129. Zhejiang Langhua Pharmaceutical Corporation Information
Table 130. Zhejiang Langhua Pharmaceutical Description and Major Businesses
Table 131. Zhejiang Langhua Pharmaceutical Product Features and Attributes
Table 132. Zhejiang Langhua Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Zhejiang Langhua Pharmaceutical Recent Developments
Table 134. Kingchem (Liaoning) Life Science Corporation Information
Table 135. Kingchem (Liaoning) Life Science Description and Major Businesses
Table 136. Kingchem (Liaoning) Life Science Product Features and Attributes
Table 137. Kingchem (Liaoning) Life Science Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Kingchem (Liaoning) Life Science Recent Developments
Table 139. Raw Materials Key Suppliers
Table 140. Distributors List
Table 141. Market Trends and Market Evolution
Table 142. Market Drivers and Opportunities
Table 143. Market Challenges, Risks, and Restraints
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Small Molecule Drug CDMO Services Product Picture
Figure 2. Global Small Molecule Drug CDMO Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Preparation Product Picture
Figure 4. Chemical API Product Picture
Figure 5. Global Small Molecule Drug CDMO Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Clinical Treatment
Figure 7. Medical Research
Figure 8. Commercial Production
Figure 9. Small Molecule Drug CDMO Services Report Years Considered
Figure 10. Global Small Molecule Drug CDMO Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 12. Global Small Molecule Drug CDMO Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Small Molecule Drug CDMO Services Revenue Market Share by Region (2020-2031)
Figure 14. Global Small Molecule Drug CDMO Services Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Preparation Revenue Market Share by Player in 2024
Figure 17. Chemical API Revenue Market Share by Player in 2024
Figure 18. Global Small Molecule Drug CDMO Services Revenue Market Share by Type (2020-2031)
Figure 19. Global Small Molecule Drug CDMO Services Revenue Market Share by Application (2020-2031)
Figure 20. North America Small Molecule Drug CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players Small Molecule Drug CDMO Services Revenue (US$ Million) in 2024
Figure 22. North America Small Molecule Drug CDMO Services Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America Small Molecule Drug CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 24. US Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 25. Canada Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 27. Europe Small Molecule Drug CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players Small Molecule Drug CDMO Services Revenue (US$ Million) in 2024
Figure 29. Europe Small Molecule Drug CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe Small Molecule Drug CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 32. France Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 34. Italy Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 35. Russia Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Small Molecule Drug CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players Small Molecule Drug CDMO Services Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific Small Molecule Drug CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific Small Molecule Drug CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 41. Japan Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 43. Australia Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 44. India Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore Small Molecule Drug CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America Small Molecule Drug CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players Small Molecule Drug CDMO Services Revenue (US$ Million) in 2024
Figure 52. Central and South America Small Molecule Drug CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America Small Molecule Drug CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil Small Molecule Drug CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina Small Molecule Drug CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa Small Molecule Drug CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players Small Molecule Drug CDMO Services Revenue (US$ Million) in 2024
Figure 58. South America Small Molecule Drug CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa Small Molecule Drug CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries Small Molecule Drug CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 61. Israel Small Molecule Drug CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt Small Molecule Drug CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa Small Molecule Drug CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 64. Small Molecule Drug CDMO Services Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
